) --Welcome to September's Biotech Stock Live Chat. The floor is yours.

It's been a while since I did one of these chats, so a review of the ground rules: I'm here for the next 90 minutes to answer your biotech-investing questions and, hopefully, spark some interactive debate on the hot topics of the day. This chat only works if you participate, so please keep the questions and comments flowing.

If you're at a loss for topics, I have some suggestions that riff off my

2012 Biotech Stock Fall Preview




(VVUS) - Get VIVUS, Inc. Report

announcing the commercial launch of Qsymia on Monday, the weight-loss market share war with

Arena Pharmaceuticals

(ARNA) - Get Arena Pharmaceuticals, Inc. Report

ratchets up a notch.


(AMRN) - Get Amarin Corporation Plc Sponsored ADR Report

: NCE status, when? Vascepa launch? Takeout or partnership?

Let's debate

Sunesis Pharmaceuticals

(SNSS) - Get Sunesis Pharmaceuticals, Inc. Report


Cyclacel Pharmaceuticals

(CYCC) - Get Cyclacel Pharmaceuticals, Inc. Report

. Which company has the better drug for acute myeloid leukemia?


Acadia Pharmaceuticals

(ACAD) - Get ACADIA Pharmaceuticals Inc. Report

and its Parkinson's disease drug pimavanserin succeed in the current phase III trial?



(EXEL) - Get Exelixis, Inc. Report


Ariad Pharmaceuticals


garner early FDA approval for their respective cancer drugs?

Let's look ahead to see what's in store for hepatitis C drug stocks like

TheStreet Recommends

Gilead Sciences

(GILD) - Get Gilead Sciences, Inc. (GILD) Report


Idenix Pharmaceuticals



Vertex Pharmaceuticals

(VRTX) - Get Vertex Pharmaceuticals Incorporated Report



Peregrine Pharmaceuticals


sign a partner before starting the bavituximab phase III lung cancer study at year's end, as promised?

Sarepta Therapeutics

(SRPT) - Get Sarepta Therapeutics, Inc. Report


Let's talk about these stocks today, or any other biotech -investing subject that piques your interest. Please join me live.

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here:

Adam Feuerstein


>To follow the writer on Twitter, go to


>To submit a news tip, send an email to:






and become a fan on


Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback;

click here

to send him an email.